These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 25486598

  • 1. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
    Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, Blockus H, Boylan JF, Ferreira C, Puget S, Abely M, Vassal G, Grill J, Geoerger B.
    Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
    [Abstract] [Full Text] [Related]

  • 2. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D.
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [Abstract] [Full Text] [Related]

  • 3. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
    Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J, Vassal G.
    Int J Cancer; 2008 Jul 01; 123(1):209-16. PubMed ID: 18386816
    [Abstract] [Full Text] [Related]

  • 4. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
    Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA.
    Pediatr Blood Cancer; 2012 May 01; 58(5):815-8. PubMed ID: 22052798
    [Abstract] [Full Text] [Related]

  • 5. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
    Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Røtne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF.
    Cancer Res; 2009 Oct 01; 69(19):7672-80. PubMed ID: 19773430
    [Abstract] [Full Text] [Related]

  • 6. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.
    Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, Shang S, Pavlick A, Shao Y, Darvishian F, Boylan JF, Osman I, Hernando E.
    PLoS One; 2011 Oct 01; 6(9):e25264. PubMed ID: 21980408
    [Abstract] [Full Text] [Related]

  • 7. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.
    Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA.
    Breast Cancer Res Treat; 2012 Jul 01; 134(2):495-510. PubMed ID: 22547109
    [Abstract] [Full Text] [Related]

  • 8. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.
    He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, Cai J, Higgins B, Kolinsky K, Rizzo C, Packman K, Heimbrook D, Boylan JF.
    Mol Oncol; 2011 Jun 01; 5(3):292-301. PubMed ID: 21315665
    [Abstract] [Full Text] [Related]

  • 9. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
    Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, Razak AA, Chen EX, Brana I, Wizemann M, Wang L, Siu LL, Bedard PL.
    Invest New Drugs; 2013 Oct 01; 31(5):1182-91. PubMed ID: 23860641
    [Abstract] [Full Text] [Related]

  • 10. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
    Nair JS, Sheikh T, Ho AL, Schwartz GK.
    Anticancer Res; 2013 Apr 01; 33(4):1307-16. PubMed ID: 23564767
    [Abstract] [Full Text] [Related]

  • 11. Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation.
    Dell'albani P, Rodolico M, Pellitteri R, Tricarichi E, Torrisi SA, D'Antoni S, Zappia M, Albanese V, Caltabiano R, Platania N, Aronica E, Catania MV.
    Neuro Oncol; 2014 Jan 01; 16(2):204-16. PubMed ID: 24305720
    [Abstract] [Full Text] [Related]

  • 12. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
    Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LM, van Hoof SJ, Groot AJ, Habets R, Prickaerts J, Chalmers AJ, Eekers DB, Theys J, Short SC, Verhaegen F, Vooijs M.
    Oncotarget; 2016 Jul 05; 7(27):41251-41264. PubMed ID: 27183910
    [Abstract] [Full Text] [Related]

  • 13. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
    Wang L, Dai G, Yang J, Wu W, Zhang W.
    Med Sci Monit; 2018 Jun 14; 24():4046-4053. PubMed ID: 29899322
    [Abstract] [Full Text] [Related]

  • 14. Notch promotes radioresistance of glioma stem cells.
    Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA.
    Stem Cells; 2010 Jan 14; 28(1):17-28. PubMed ID: 19921751
    [Abstract] [Full Text] [Related]

  • 15. GASC1 promotes glioma progression by enhancing NOTCH1 signaling.
    Xiao Z, Yang X, Liu Z, Shao Z, Song C, Zhang K, Wang X, Li Z.
    Mol Med Rep; 2021 May 14; 23(5):. PubMed ID: 33649841
    [Abstract] [Full Text] [Related]

  • 16. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
    Gilbert CA, Daou MC, Moser RP, Ross AH.
    Cancer Res; 2010 Sep 01; 70(17):6870-9. PubMed ID: 20736377
    [Abstract] [Full Text] [Related]

  • 17. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
    Groeneweg JW, Hall TR, Zhang L, Kim M, Byron VF, Tambouret R, Sathayanrayanan S, Foster R, Rueda BR, Growdon WB.
    Gynecol Oncol; 2014 Jun 10; 133(3):607-15. PubMed ID: 24667249
    [Abstract] [Full Text] [Related]

  • 19. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
    Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA.
    Cancer; 2015 Feb 01; 121(3):432-440. PubMed ID: 25250858
    [Abstract] [Full Text] [Related]

  • 20. Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation.
    Zhao N, Guo Y, Zhang M, Lin L, Zheng Z.
    Oncol Rep; 2010 May 01; 23(5):1443-7. PubMed ID: 20372862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.